摘要
目的观察参麦注射液联合化疗治疗晚期胃癌的临床疗效和对于血管内皮生长因子（VEGF）、基质金属蛋白酶-3（MMP-3）表达水平的影响。方法将80例晚期胃癌随机分为两组：参麦组40例，用参麦联合DCF方案化疗，对照组40例，单纯用DCF方案化疗。2个周期后评价疗效、毒副反应、生活质量，检测患者血清VEGF、MMP-3水平。结果参麦组有效率45％，对照组37．5％，差异无统计学意义（P〉0．05），但参麦组较对照组毒副反应降低，生活质量提高，差异有统计学意义（P〈0．05）。两组治疗后VEGF、MMP-3水平均较治疗前明显下降（P〈0．01），且参麦组下降幅度优于对照组，差异有统计学意义（P〈0．05）。结论参麦注射液可以减轻晚期胃癌患者化疗毒副反应，改善生活质量，降低VEGF和MMP-3的表达水平。
Objective To observe the clinical effects of Shenmai injection （ SMI ） combined with chemotherapy in treating advanced gastric cancer （ AGC ） and its impacts on the expression levels of vascular endothelial growth factor （ VEGF ） and matrix metallopeptidase 3 （ MMP- 3 ） . Methods 80 AGC patients were randomly divided into two groups, the SMI group （ 40 patients, performed Shenmai injection plus DCF chemotherapy ） and the control group （ 40 patients, performed DCF chemotherapy alone ） . The efficacies, toxicities, life qualities, and serum levels of VEGF and MMP-3 were evaluated after two treatment courses. Results The efficacy rate in the SMI group was 45%, and that in the control group was 37.5%, no significant difference was found, but the toxicity in the SMI group was reduced than the control group, and the quality of life was improved, and the differences were statistically significant （ P〈0.05 ） . After the treatment, the VEGF and MMP-3 levels in both groups were significantly decreased than those before the treatment （ P〈0.01 ） , and the declined degree in the SMI group was statistically better than the control group （ P〈0.05 ） . Conclusions SMI could reduce the side effects of chemotherapy in AGC patients, improve their qualities of life, and reduce the expression levels of VEGF and MMP-3.
出处
《浙江临床医学》
2017年第2期248-250,共3页
Zhejiang Clinical Medical Journal
基金
浙江省医学会临床科研资金项目（2013ZYC-A102）
关键词
胃肿瘤
参麦注射液
血管内皮生长因子
基质金属蛋白酶-3
Gastric tumor Shenmai injection Vascular endothelial growth factor Matrix metalloproteinase-3
